BR112018069483A2 - pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis. - Google Patents
pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis.Info
- Publication number
- BR112018069483A2 BR112018069483A2 BR112018069483A BR112018069483A BR112018069483A2 BR 112018069483 A2 BR112018069483 A2 BR 112018069483A2 BR 112018069483 A BR112018069483 A BR 112018069483A BR 112018069483 A BR112018069483 A BR 112018069483A BR 112018069483 A2 BR112018069483 A2 BR 112018069483A2
- Authority
- BR
- Brazil
- Prior art keywords
- cleavable groups
- prodrugs
- enzymatically cleavable
- cytotoxic drug
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis. a presente invenção refere-se a novos pró-fármacos ou conjugados de fórmula geral (ia) (ia) em que os fármacos citotóxicos, por exemplo inibidores da proteína do fuso de cinesina, são mascarados com grupos cliváveis por legumain e, assim, liberam o fármaco e uso desses pró-fármacos ou conjugados para tratamento e/ou prevenção de doenças e uso desses pro fármacos ou conjugados para produção de medicamentos para tratamento e/ou prevenção de doenças, especialmente de distúrbios hiperproliferativos e/ou angiogênicos, por exemplo, cânceres.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16162400 | 2016-03-24 | ||
EP16205988 | 2016-12-21 | ||
PCT/EP2017/056684 WO2017162663A1 (de) | 2016-03-24 | 2017-03-21 | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018069483A2 true BR112018069483A2 (pt) | 2019-07-30 |
Family
ID=58361030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018069483A BR112018069483A2 (pt) | 2016-03-24 | 2017-03-21 | pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis. |
Country Status (18)
Country | Link |
---|---|
US (2) | US11685714B2 (pt) |
EP (1) | EP3432934B1 (pt) |
JP (1) | JP7251981B2 (pt) |
KR (1) | KR20180123047A (pt) |
CN (2) | CN116059390A (pt) |
AU (1) | AU2017236431A1 (pt) |
BR (1) | BR112018069483A2 (pt) |
CA (1) | CA3018630A1 (pt) |
CL (1) | CL2018002699A1 (pt) |
CO (1) | CO2018010026A2 (pt) |
IL (1) | IL261758A (pt) |
MX (1) | MX2018011627A (pt) |
PE (1) | PE20181852A1 (pt) |
RU (1) | RU2018136778A (pt) |
SG (2) | SG10202008909VA (pt) |
TW (1) | TW201735954A (pt) |
UY (1) | UY37168A (pt) |
WO (1) | WO2017162663A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017017172A (es) | 2015-06-22 | 2018-02-23 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
CA2990398A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies |
AU2016282724A1 (en) | 2015-06-23 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of KSP inhibitors |
AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
JP7174704B2 (ja) * | 2016-12-21 | 2022-11-17 | バイエル・アクチエンゲゼルシヤフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
KR102556826B1 (ko) * | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
SG11202012608VA (en) * | 2018-06-18 | 2021-02-25 | Bayer Ag | Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN110428870B (zh) * | 2019-08-08 | 2023-03-21 | 苏州泓迅生物科技股份有限公司 | 一种预测抗体重链轻链配对概率的方法及其应用 |
CN113754541A (zh) * | 2020-06-02 | 2021-12-07 | 深圳湾实验室 | 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用 |
WO2022167052A1 (en) * | 2021-02-08 | 2022-08-11 | Y-Mabs Therapeutics, Inc. | Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies |
EP4294453A1 (en) * | 2021-02-16 | 2023-12-27 | Glykos Finland Oy | Linker-payloads and conjugates thereof |
CN112979491B (zh) * | 2021-02-24 | 2022-04-15 | 中国药科大学 | 一种包含过氧化氢/组织蛋白酶l响应性保护基的化合物及其应用 |
WO2024105205A1 (en) | 2022-11-17 | 2024-05-23 | Bayer Aktiengesellschaft | Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
DE8808645U1 (pt) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen, De | |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
ES2133139T3 (es) | 1989-10-20 | 1999-09-01 | Medarex Inc | Hetero anticuerpos biespecificos con funciones efectoras dobles. |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
ATE175118T1 (de) | 1990-10-05 | 1999-01-15 | Medarex Inc | Gezielte immunostimulierung mit bispezifischen stoffen |
DE69128253T2 (de) | 1990-10-29 | 1998-06-18 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
HU219537B (hu) | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
DE69214709T2 (de) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | Neue Antikörper und Verfahren zu ihrer Verwendung |
CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
DK0719859T3 (da) | 1994-12-20 | 2003-10-20 | Merck Patent Gmbh | Anti-alfa V-integrin monoklonalt antistof |
AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
ES2260788T3 (es) | 1996-03-25 | 2006-11-01 | Medarex, Inc. | Anticuerpos monoclonales especificos para el dominio estracelular de antigeno de membrana especifico de la prostata. |
IL147638A0 (en) | 1999-07-29 | 2002-08-14 | Medarex Inc | Human monoclonal antibodies to prostate specific membrane antigen |
US7129332B2 (en) | 2000-02-25 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
JP2003533987A (ja) | 2000-05-19 | 2003-11-18 | イス ケミカル カンパニー リミテッド | 表皮成長因子収容体に対するヒト化抗体 |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
WO2003083041A2 (en) | 2002-03-22 | 2003-10-09 | Biogen, Inc. | Cripto-specific antibodies |
DK1390389T3 (da) | 2001-04-26 | 2009-04-20 | Biogen Idec Inc | Cripto-blokerende antistoffer og anvendelser deraf |
DK2163256T3 (en) | 2001-05-11 | 2015-12-07 | Ludwig Inst For Cancer Res Ltd | Specific binding proteins and use thereof |
CZ200438A3 (cs) | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
EP3184539A3 (en) | 2001-10-23 | 2017-09-13 | PSMA Development Company L.L.C. | Psma antibodies |
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
BR0311799A (pt) | 2002-06-14 | 2005-05-10 | Immunomedics Inc | Anticorpo monoclonal hpam4 |
US20050059592A1 (en) | 2003-04-11 | 2005-03-17 | Kiener Peter A. | EphA2 and hyperproliferative cell disorders |
CN102675462A (zh) | 2003-06-27 | 2012-09-19 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
BRPI0412879A8 (pt) | 2003-07-21 | 2015-12-15 | Immunogen Inc | Conjugado citotóxico específico do antígeno ca6 e métodos de seu uso |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
US20050142133A1 (en) | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
ES2387809T3 (es) | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
US7732131B2 (en) | 2004-08-03 | 2010-06-08 | Innate Pharma S.A. | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor |
ES2539126T3 (es) | 2004-12-09 | 2015-06-26 | Janssen Biotech, Inc. | Inmunoconjugados anti integrina, métodos para su producción y su uso |
DE602006013275D1 (de) | 2005-01-07 | 2010-05-12 | Diadexus Inc | Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür |
RU2492186C2 (ru) | 2005-02-18 | 2013-09-10 | Медарекс Ллс | Выделенное анти-cd30 антитело (варианты), хозяйская клетка, способ получения химерного или гуманизированного варианта анти-cd30 антител (варианты), способ ингибирования роста клеток cd30+ и способ ингибирования роста опухолевых клеток, экспрессирующих cd30 |
PL1912677T3 (pl) | 2005-06-20 | 2014-03-31 | Psma Dev Company L L C | Koniugaty przeciwciało PSMA-lek |
RS52470B (en) | 2005-08-24 | 2013-02-28 | Immunogen Inc. | PROCEDURE FOR PREPARATION OF PURE CONJUGATED MEDICINES |
AU2006294663B2 (en) | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP1911766A1 (en) | 2006-10-13 | 2008-04-16 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
DK2073842T4 (da) | 2006-09-10 | 2024-01-15 | Glycotope Gmbh | Anvendelse af humane celler af myloid leukæmioprindelse til udtrykkelse af anti-stoffer |
EP1900750A1 (en) | 2006-09-18 | 2008-03-19 | Glycotope Gmbh | Fully human high yield production system for improved antibodies |
EP2064240A2 (en) | 2006-09-18 | 2009-06-03 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
JP2010523478A (ja) | 2007-03-22 | 2010-07-15 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | モノクローナル抗体8h9の使用 |
NZ556142A (en) | 2007-06-25 | 2009-11-27 | Novartis Ag | Animal remedy dispensing means |
EP2545938A1 (en) | 2007-08-03 | 2013-01-16 | Abbott Biotherapeutics Corp. | Therapeutic use of anti-tweak receptor antibodies |
US9283276B2 (en) | 2007-08-14 | 2016-03-15 | Ludwig Institute For Cancer Research Ltd. | Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
UA117446C2 (uk) | 2007-08-29 | 2018-08-10 | Санофі-Авентіс | Гуманізоване антитіло до cxcr5 |
ES2424745T3 (es) | 2007-09-07 | 2013-10-08 | Agensys, Inc. | Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12 |
US8039597B2 (en) | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
DK2215121T3 (en) | 2007-11-26 | 2016-05-02 | Bayer Ip Gmbh | ANTI-mesothelin ANTIBODIES AND USES THEREOF |
AU2008331436A1 (en) | 2007-12-06 | 2009-06-11 | Csl Limited | Method of inhibition of leukemic stem cells |
PT2242772E (pt) | 2007-12-26 | 2015-02-09 | Biotest Ag | Imunoconjugados dirigidos contra cd138 e as suas utilizações |
EP2238168B8 (en) | 2007-12-26 | 2014-07-23 | Biotest AG | Agents targeting cd138 and uses thereof |
JP5555223B2 (ja) | 2008-04-02 | 2014-07-23 | マクロジェニクス,インコーポレーテッド | HER2/neu特異的抗体およびその使用方法 |
CA2723973A1 (en) | 2008-05-15 | 2009-11-19 | Biogen Idec Ma Inc. | Anti-fn14 antibodies and uses thereof |
JP5719298B2 (ja) | 2008-08-29 | 2015-05-13 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組換え抗上皮増殖因子受容体抗体組成物 |
CN102325549A (zh) | 2009-03-31 | 2012-01-18 | 罗氏格黎卡特股份公司 | 用人源化抗-EGFR IgG1抗体和伊立替康治疗癌症 |
US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
WO2010126066A1 (ja) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗IL-3Rα抗体 |
CN101959216B (zh) | 2009-07-20 | 2014-06-18 | 电信科学技术研究院 | 一种分载波配置增强cell_fach的方法、系统和设备 |
AU2010303415B2 (en) | 2009-10-07 | 2015-02-19 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
ES2619585T3 (es) | 2010-03-22 | 2017-06-26 | Lead Discovery Center Gmbh | Derivados de triazina disustituidos farmacéuticamente activos |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
JP6088488B2 (ja) | 2011-04-21 | 2017-03-01 | シアトル ジェネティックス, インコーポレイテッド | 新規な結合剤−薬物複合体(adc)およびそれらの使用 |
AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
ES2924722T3 (es) | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
MX2015004757A (es) * | 2012-10-16 | 2015-07-17 | Endocyte Inc | Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos. |
JP6272230B2 (ja) | 2012-10-19 | 2018-01-31 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート |
CN105451773A (zh) | 2013-03-15 | 2016-03-30 | 诺华股份有限公司 | 细胞增殖抑制剂及其缀合物 |
RU2016100892A (ru) | 2013-06-14 | 2017-07-19 | Байер Фарма Акциенгезельшафт | Антитела против tweakr и их применение |
RU2698697C2 (ru) | 2013-12-23 | 2019-08-29 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего (ADC) с ингибиторами KSP |
CA2951049C (en) | 2014-06-03 | 2023-01-03 | Jiarui Biopharmaceuticals, Ltd. | Peptide-drug conjugates |
WO2015189143A1 (en) | 2014-06-12 | 2015-12-17 | Bayer Pharma Aktiengesellschaft | Aglycosyl anti-tweakr antibodies and uses thereof |
EP3233127A1 (de) | 2014-12-15 | 2017-10-25 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern |
MX2017017172A (es) * | 2015-06-22 | 2018-02-23 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
WO2016207104A1 (de) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern |
AU2016282724A1 (en) | 2015-06-23 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of KSP inhibitors |
CA2990398A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies |
AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
KR102556826B1 (ko) | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
JP7174704B2 (ja) | 2016-12-21 | 2022-11-17 | バイエル・アクチエンゲゼルシヤフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
SG11202012608VA (en) | 2018-06-18 | 2021-02-25 | Bayer Ag | Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile |
-
2017
- 2017-03-21 AU AU2017236431A patent/AU2017236431A1/en not_active Abandoned
- 2017-03-21 SG SG10202008909VA patent/SG10202008909VA/en unknown
- 2017-03-21 BR BR112018069483A patent/BR112018069483A2/pt not_active Application Discontinuation
- 2017-03-21 MX MX2018011627A patent/MX2018011627A/es unknown
- 2017-03-21 PE PE2018001862A patent/PE20181852A1/es not_active Application Discontinuation
- 2017-03-21 US US16/087,928 patent/US11685714B2/en active Active
- 2017-03-21 SG SG11201808167VA patent/SG11201808167VA/en unknown
- 2017-03-21 JP JP2018549445A patent/JP7251981B2/ja active Active
- 2017-03-21 CN CN202211097986.XA patent/CN116059390A/zh active Pending
- 2017-03-21 WO PCT/EP2017/056684 patent/WO2017162663A1/de active Application Filing
- 2017-03-21 CA CA3018630A patent/CA3018630A1/en active Pending
- 2017-03-21 CN CN201780019957.2A patent/CN108883195A/zh active Pending
- 2017-03-21 EP EP17712140.7A patent/EP3432934B1/de active Active
- 2017-03-21 RU RU2018136778A patent/RU2018136778A/ru not_active Application Discontinuation
- 2017-03-21 KR KR1020187027099A patent/KR20180123047A/ko not_active Application Discontinuation
- 2017-03-24 TW TW106109896A patent/TW201735954A/zh unknown
- 2017-03-24 UY UY0001037168A patent/UY37168A/es not_active Application Discontinuation
-
2018
- 2018-09-13 IL IL261758A patent/IL261758A/en unknown
- 2018-09-24 CO CONC2018/0010026A patent/CO2018010026A2/es unknown
- 2018-09-24 CL CL2018002699A patent/CL2018002699A1/es unknown
-
2023
- 2023-02-27 US US18/175,265 patent/US20240043379A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2018010026A2 (es) | 2018-09-28 |
PE20181852A1 (es) | 2018-12-03 |
US20240043379A1 (en) | 2024-02-08 |
US20190077752A1 (en) | 2019-03-14 |
CL2018002699A1 (es) | 2019-01-18 |
CN116059390A (zh) | 2023-05-05 |
US11685714B2 (en) | 2023-06-27 |
TW201735954A (zh) | 2017-10-16 |
JP7251981B2 (ja) | 2023-04-04 |
RU2018136778A (ru) | 2020-04-24 |
EP3432934A1 (de) | 2019-01-30 |
AU2017236431A2 (en) | 2018-11-08 |
KR20180123047A (ko) | 2018-11-14 |
SG11201808167VA (en) | 2018-10-30 |
AU2017236431A1 (en) | 2018-09-27 |
CN108883195A (zh) | 2018-11-23 |
SG10202008909VA (en) | 2020-10-29 |
MX2018011627A (es) | 2019-01-10 |
IL261758A (en) | 2018-10-31 |
WO2017162663A1 (de) | 2017-09-28 |
UY37168A (es) | 2017-10-31 |
JP2019512517A (ja) | 2019-05-16 |
EP3432934B1 (de) | 2022-02-23 |
CA3018630A1 (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018069483A2 (pt) | pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis. | |
MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
BR112018015474A2 (pt) | agonista de fxr derivado de esteroide | |
CL2018002718A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
BR112018005861A2 (pt) | derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos | |
GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
CO7160008A2 (es) | Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos | |
BR112015019412A2 (pt) | inibidores de bace1 | |
BR112019025230A2 (pt) | Anéis 5-5 fundidos como inibidores de c5a | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
BR112018011178A2 (pt) | sais de conjugados para terapia de câncer | |
BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
CL2022001970A1 (es) | Conjugados de proteínas-compuestos antivirales | |
BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
BR112016027383A8 (pt) | derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação | |
BR112015017483A2 (pt) | uso de sais de tungstênio (iv) para o tratamento da infertilidade feminina em mamíferos não diabéticos | |
BR112018007673A2 (pt) | ?análogos de epotilona, métodos de síntese, métodos de tratamento e conjugados de fármaco dos mesmos? | |
BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo | |
BR112022024700A2 (pt) | Inibidores de atr e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |